PhAST key facts
as of Oct 2026- Developer of an imaging technology designed to transform the fight against infectious diseases.
- PhAST is valued at approximately $241.7M as of Oct 2026 (last reported valuation).
- It has raised $18.6M; the latest was Later Stage VC ($3.5M) in Apr 2025.
- Notable investors include Endless Frontier Labs, Labcorp Venture Fund, DAYLI Partners, BlueLion Incubator, Laboratory Corporation of America — 10 tracked in total.
- Status: Privately Held (backing).
PhAST's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch PhAST: the Monday email on marks, rounds and moves
PhAST funding rounds
No funding rounds for PhAST are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
PhAST valuation
PhAST's last reported valuation was $242 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
PhAST investors
10 investors are on record for PhAST, including Endless Frontier Labs, Labcorp Venture Fund, DAYLI Partners and BlueLion Incubator.
About PhAST
Developer of an imaging technology designed to transform the fight against infectious diseases. The company's technology uses artificial intelligence and machine learning to harness the immediate and extensive information that imaging reveals about pathogens, enabling healthcare providers to improve patient recovery.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 28
- Website
- phast.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.